Embargoed until: Publicly released:
Australian and Kiwi children with a severe form of epilepsy had a 43.5 per cent drop in how many seizures they were having after taking a CBD gel twice daily for around six months, reports a new study. The researchers found adverse effects from the gel on the group of almost 50 children, aged 3 to 18, were either mild or moderate. The study team notes that the research was non-randomised and had no control group, so it’s not possible to know if the placebo effect may have had an impact.
Journal/conference: JAMA Network Open
Link to research (DOI): 10.1001/jamanetworkopen.2021.23930
Organisation/s: The University of Melbourne, Murdoch Children’s Research Institute (MCRI), University of Otago, Consultants, USA; The Griesser Group, USA; Zynerba Pharmaceuticals, USA
Funder: The study was supported by Zynerba Pharmaceuticals Inc. : The sponsor was responsible for the design and conduct of the study. The sponsor was involved with the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. Dr Scheffer reported service on the editorial boards of the Annals of Neurology, Neurology, and Epileptic Disorders; she reported patents held or pending for therapeutic compounds, testing methods, and molecular diagnostic targets for infantile epilepsy, some of which are licensed and have paid royalties. She reported service on scientific advisory boards for UCB Pharmaceuticals, Eisai Co Ltd, GlaxoSmithKline, BioMarin Pharmaceutical, Nutricia, Rogcon Inc, Chiesi, Encoded Therapeutics, Xenon Pharmaceuticals, Zynerba Pharmaceuticals, and Knopp Biosciences; she reported receiving speaker honoraria from GlaxoSmithKline, UCB Pharmaceuticals, BioMarin, Athena Diagnostics, Liva Nova, Biocodex, and Eisai; she reported receiving funding for travel from UCB Pharmaceuticals, Biocodex, GlaxoSmithKline, Biomarin Pharmaceutical, National Research Foundation Singapore, and Eisai Co Ltd; she reported service as an investigator for Zogenix, Zynerba Pharmaceuticals, Ultragenyx, GW Pharmaceuticals, UCB Pharmaceuticals, Eisai Co Ltd, Anavex Life Sciences, Ovid Therapeutics, Epigenyx, Encoded Therapeutics, and Marinus; and she reported consulting work for Zynerba Pharmaceuticals, Athena Diagnostics, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium, and UCB Pharmaceuticals. She reported receiving research support from the National Health and Medical Research Council of Australia, the Australian Medical Research Future Fund, Health Research Council of New Zealand, Citizens United for Research in Epilepsy, Australian Epilepsy Research Fund, and the National Institute of Neurological Disorders and Stroke outside the submitted work. Dr Sadleir reported consulting work for Zynerba Pharmaceuticals Inc, and reported receiving honoraria from Eisai Co Ltd. Drs Hulihan and Messenheimer and Mr Griesser reported consulting work for Zynerba Pharmaceuticals Inc. Dr Gutterman and Ms Sebree reported employment with Zynerba Pharmaceuticals Inc and reported stock options from Zynerba Pharmaceuticals Inc; they reported holding patents for treatment methods using cannabidiol and CBD. Ms Sebree reported stock ownership of Zynerba Pharmaceuticals Inc. No other conflicts were reported.
Recent Comments